AnalysisNews

MDWD today

$13.28-$0.54 (-3.94%)close Nov 12, 2026

Trend

DailyDowntrend (confirmed)

4 hourLeaning Bearish

1 hourStrong Bearish

15 minBullish

5 minStrong Bearish

Daily trend turns up above $12.89

Key levels

Resistance$14.84

Resistance$13.99

Support$12.73

Support$11.80

Latest news & SEC filings

DealMediWound Ltd. closes $17.25 million public offering

DealMediWound raises $15 million by selling ordinary shares to the public

DealMediWound sets $15M bought deal at $12.50 per share

All MDWD news →

About MediWound

MediWound is a biopharmaceutical company that develops and commercializes products based on a patented enzymatic technology platform. Its lead product, NexoBrid, is approved for removing eschar from severe thermal burns in the United States, European Union, and other international markets. The company is also developing EscharEx for chronic wound debridement and other pipeline candidates. It operates manufacturing facilities in Israel and sells to burn centers and specialists through commercial partners.

Based on the company's 20-F filed Mar 5, 2026.

Nasdaq · Healthcare

MediWound Ltd. (MDWD)

$13.82-0.29 (-2.06%)
WATCHLISTGrade: ARisk: MEDIUM
1D5D1M1Y5YMaxSign up for all timeframes
12.3312.8113.2913.7713.82Oct 9Oct 19Oct 27Nov 4
High14.11
Low13.62
Open14.11
Volume142K
Avg Vol115K
VWAP13.81
30d High14.25
30d Low11.85
30d Chg+1.62%

What Is the Price Target for MDWD?

SEPT Low Target

$30.00

SEPT Mid Target

$33.00

SEPT High Target

$36.00

Analyst Consensus

$33.00

Current: $12.97Upside: +154.4%Confidence: 40%Method: Analyst Consensus

Is MDWD a Buy or Sell Right Now?

76
Investability Score
WATCHLIST12-18 months
News summary · last 30 days
Nov 12NeutralEarningsInsider buy6 articles
MediWound (MDWD) reported third-quarter 2026 results, posting a loss of $0.65 per share that beat the $0.71 forecast but revenue of $3.600 million that fell well short of the $6.728 million estimate. Despite the revenue miss, the stock closed up 2.94% at $12.97, trading between a low of $12.46 and a high of $13.53 on volume of 347,841 shares. The company also filed multiple Form 4 insider trading reports, though these had low expected impact. The mixed earnings picture—a narrower loss offset by weak sales—creates an uncertain signal, with the market's positive price reaction suggesting investors may be focusing on the bottom-line beat.
Critical news
Nov 12HIGHEarnings: growth/beat
Nov 12HIGHEarnings: growth/beat

Thesis

  • •Revenue growing -16.1% YoY with ACCELERATING trend — accelerating momentum.
  • •Smart money flows are positive — institutional and insider activity shows net buying.

AI-Powered Trading Signals

Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for MDWD.

Start Free Trial →

Is MDWD Overvalued or Undervalued?

Valuation Verdict

UNDERVALUED

Methods Used

Analyst Consensus

Fair Value

$33.00

27

Moat Score

NONE

5/9

Piotroski Score

-1.8

Altman Z-Score

What Is Smart Money Doing with MDWD?

Insider Signal

BUYING

7 buys / 3 sells (90d)

Congress Signal

NEUTRAL

0 buys / 0 sells (90d)

Institutional

N/A

Short Squeeze Risk

HIGH

Signal: HIGH_SHORT_INTEREST

Recent Insider Activity

NameTitleTypeSharesValueDate
Rubinstein SamueldirectorSale525$7KSep 1, 2026
Rubinstein SamueldirectorBuy525$7KSep 1, 2026
Hess ShmuelofficerSale1,979$25KAug 27, 2026
Hess ShmuelofficerSale1,865$24KAug 26, 2026
SHAMIR NACHUMdirectorBuy175$2KJun 3, 2026
SHAMIR NACHUMdirectorBuy5,825$82KJun 3, 2026
Fox David MortondirectorBuy1,730$25KJun 1, 2026
Fox David MortondirectorBuy10$142.30Jun 1, 2026
Fox David MortondirectorBuy1,797$25KJun 1, 2026
Rubinstein SamueldirectorBuy150$2KMay 29, 2026

Track Smart Money Across 4,000+ Stocks

Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.

See All Smart Money Signals →

MDWD Growth Story

Revenue YoY

-16.1%

3yr Revenue CAGR

-13.8%

EPS Growth YoY

30.69%

FCF Growth YoY

-8.7%

Revenue Trend

ACCELERATING

Dark Pool Trades for MDWD

PREVIEW

SEPT Investing tracks real-time dark pool institutional trades for MDWD, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.

TimePriceSizeValueSide
20:53:21$13.762,200$$30KBUY
19:02:21$13.8611,200$$155KBUY
19:01:55$13.6211,200$$153KSELL
15:56:10$13.931,445$$20KBUY
15:37:10$13.811,251$$17KSELL

5 dark pool trades shown · $$375K preview volume

Real-time institutional flow, block trades, and net positioning

See all dark pool activity

Options Flow for MDWD

PREVIEW

SEPT Investing provides real-time options flow tracking for MDWD, including unusual sweep detection, block trades, and dealer positioning. Each trade shows strike, expiry, premium, implied volatility, and greek values for informed decision-making.

TypeStrikeExpiryDTEPremiumSizeTrade
CALL$14Jun 17218$$25.5K100BLOCK
CALL$14Nov 209$$301SWEEP
CALL$14Nov 209$$903SWEEP
CALL$14Nov 209$$903SWEEP
CALL$14Nov 209$$903SWEEP

5 options trades shown · 100% calls

Unusual activity, GEX levels, max pain, and dealer positioning

See full options flow

Full AI Research Report

SEPT's Trading AI has generated a free, downloadable PDF research report for MediWound Ltd. (MDWD) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.

Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (6 articles analyzed), and SEC filing intelligence...

AI-Powered Trading Signals.

Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.

Try SEPT Free for 7 Days →

MDWD — frequently asked questions

What is MDWD stock price today?

MediWound Ltd. (MDWD) is at $13.28, down 3.94% (-$0.54) at the Nov 12, 2026 close.

Why is MDWD stock down today?

Nov 12, 2026: MediWound (MDWD) reported third-quarter 2026 results, posting a loss of $0.65 per share that beat the $0.71 forecast but revenue of $3.600 million that fell well short of the $6.728 million estimate. Despite the revenue miss, the stock closed up 2.94% at $12.97, trading between a low of $12.46 and a high of $13.53 on volume of 347,841 shares.

What is the MDWD price target?

The average analyst price target for MDWD is $33.00, ranging from $30 to $36, based on 2 analysts. Latest: Oppenheimer maintains on Aug 14, 2026.

What do analysts rate MDWD?

Analyst ratings for MDWD: 0 Buy, 3 Hold, 0 Sell — consensus Hold.

Did MDWD beat earnings?

MDWD last reported on Nov 12, 2026: EPS -$0.46 vs -$0.71 expected — a beat of 35.2%.

Does MDWD pay a dividend?

MDWD does not currently pay a dividend.

What are MDWD support and resistance levels?

Support: $12.73, $11.80. Resistance: $13.99, $14.84, $16.03.

What are insiders doing with MDWD?

Insider activity: BUYING, 7 buys and 3 sells in the last 90 days.

What is the latest news on MDWD?

Nov 6, 2026: MediWound Ltd. closes $17.25 million public offering · Nov 4, 2026: MediWound raises $15 million by selling ordinary shares to the public · Nov 3, 2026: MediWound sets $15M bought deal at $12.50 per share